MTOR and cancer: Inhibition of the rate-limiting enzyme in guanylate nucleotide synthesis, inosine monophosphate dehydrogenase (IMPDH), selectively kills mTORC1-activated cancer cells, implying that targeting nucleotide metabolism is promising for treating tumors with elevated mTOR signaling (Valvezan et al., 2017).